Cover Image
市場調查報告書

結締組織生長因子 (胰島素樣成長因素結合蛋白質8,肥大軟骨細胞特別蛋白質24) - 開發中產品分析

Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 358690
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
結締組織生長因子 (胰島素樣成長因素結合蛋白質8,肥大軟骨細胞特別蛋白質24) - 開發中產品分析 Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Pipeline Review, H2 2016
出版日期: 2016年09月21日 內容資訊: 英文 64 Pages
簡介

結締組織生長因子 (CTGF) ,又稱為CCN2,是細胞外矩陣相關的肝素結合蛋白質的CCN家族的矩陣細胞的蛋白質。

本報告提供結締組織生長因子 (胰島素樣成長因素結合蛋白質8,肥大軟骨細胞特別蛋白質24)的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等系統性資訊。

目錄

簡介

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

開發中的產品:各企業

治療藥的評估

  • 各單劑/聯合治療
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • FibroGen, Inc.
  • RXi Pharmaceuticals Corporation

藥物簡介

暫停的計劃

開發中止的產品

最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0526TDB

Summary

Global Markets Direct's, 'Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Pipeline Review, H2 2016', provides in depth analysis on Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted pipeline therapeutics.

The report provides comprehensive information on the Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF)
  • The report reviews Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) Overview
  • Therapeutics Development
    • Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Products under Development by Stage of Development
    • Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Products under Development by Therapy Area
    • Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Products under Development by Indication
  • Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Products under Development by Companies
  • Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Companies Involved in Therapeutics Development
    • FibroGen, Inc.
    • ProMetic Life Sciences Inc.
    • RXi Pharmaceuticals Corporation
  • Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Drug Profiles
    • Antisense RNAi Oligonucleotide to Inhibit CTGF for PVR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OLX-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OLX-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pamrevlumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PBI-4050 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RXI-109 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RXI-209 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Dormant Projects
  • Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Discontinued Products
  • Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Featured News & Press Releases
    • Jun 09, 2016: ProMetic to present new data on how PBI-4050 keeps pancreatic beta cells alive at the American Diabetic Associations upcoming annual meeting
    • May 18, 2016: Health Canada authorizes ProMetic to proceed with its PBI-4050 clinical trial in patients with cystic fibrosis
    • Apr 28, 2016: RXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical Delivery of sd-rxRNA to the Cornea in an in vivo Corneal Wound Model
    • Apr 26, 2016: ProMetic PBI-4050: efficacy further evidenced in type 2 diabetic and metabolic syndrome clinical trial
    • Apr 25, 2016: RXi Pharmaceuticals to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference
    • Apr 19, 2016: RXi Pharmaceuticals Fortifies its Novel RNAi Patent Portfolio with Notice of Allowance for Lead Clinical Candidate RXI-109
    • Apr 14, 2016: ProMetic confirms PBI-4050 Anti-Fibrotic Effect in Nash Model and on Human Hepatic Stellate Cells
    • Mar 31, 2016: Rxi Pharmaceuticals Strengthens Intellectual Property Portfolio for Dermal Indications
    • Mar 28, 2016: RXi Pharmaceuticals to Present at the Oligonucleotide Therapeutics and Delivery Conference
    • Mar 22, 2016: ProMetic confirms PBI-4050 positive effects on novel biomarkers in patients suffering from metabolic syndrome and Type 2 diabetes
    • Mar 15, 2016: ProMetic announces the addition of scleroderma to PBI-4050 targeted indications
    • Mar 11, 2016: FibroGen Announces Publication of Phase 2 Study Results Supporting the Potential of FG-3019 to Treat Patients With Idiopathic Pulmonary Fibrosis
    • Jan 27, 2016: FibroGen Announces Early Phase 2 Data From a Clinical Study of FG-3019 in Combination With Chemotherapy as Neoadjuvant in Locally Advanced, Unresectable Pancreatic Cancer
    • Jan 06, 2016: FibroGen Enrolls First Patients in Phase 2 Clinical Study of Anti-Fibrotic Drug Candidate FG-3019 for the Treatment of Duchenne Muscular
    • Dec 14, 2015: Prometic's PBI-4050 To Target Cystic Fibrosis As Its Next Orphan Indication
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by FibroGen, Inc., H2 2016
  • Pipeline by ProMetic Life Sciences Inc., H2 2016
  • Pipeline by RXi Pharmaceuticals Corporation, H2 2016
  • Dormant Projects, H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top